Metabolic & Cardiometabolic
ezetimibe decreases liver fat
Part of: 💊 ezetimibe
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Ezetimibe modestly reduces hepatic fat and liver enzymes in NAFLD (meta-analysis; and ezetimibe+rosuvastatin beat rosuvastatin alone on MRI liver fat in ESSENTIAL) - a plausible incidental benefit of a statin+ezetimibe regimen. Surrogate-level only; no proof it reverses fibrosis or improves clinical liver outcomes.
The evidence (8)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Esim O et al 2025 · study_type: animal | animal | supports | low | High-fat-diet NAFLD rat model treated with free ezetimibe vs RBC-membrane-coated or uncoated PLGA nanoparticle-encapsulated ezetimibe; all ezetimibe-treated groups (including free-drug) showed significant reductions in hepatic lipid accumul |
| Patel 2016 · Therap Adv Gastroenterol | observational | supports | moderate | MRI-PDFF validation in NASH: quantifies hepatic-fat decline used as endpoint in ezetimibe trials |
| Cho Y, et al. (ESSENTIAL) 2022 · BMC Med | RCT | supports | low | [FT-verified] ESSENTIAL open-label per-protocol n=64 combo(eze+rosuva) MD 3.2%; ezetimibe added effect, no fibrosis; not blinded/placebo ↩ SUPERSEDED — pooled in the review above, counted once |
| Jiao B, Wang B, Liu B, Zhao J, Zhang Y 2024 · Front Endocrinol | meta-analysis | contradicts | low | [FT-verified 2026-08-25] Jiao 2024, 10 RCTs / 578 NAFLD-NASH patients, ezetimibe 10 mg/d; only 1 of 10 control arms was placebo. LIVER FAT IS NULL ON EVERY ENDPOINT THE PAPER MEASURED: MRI-PDFF k=2/n=109, MD -2.44 (95% CI -5.25, 0.37), P=0.09, I2=0%; histologic steatosis k=2/n=67, MD 0.00 (-0.16, 0.16), P=1.00; NAS k=3/n=107, P=0.37; ballooning P=0.68; LSM k=2/n=120, P=0.91; fibrosis k=2/n=75, P=0.69. Authors' own summary: 'no marked improvements were noted in levels of ALT, TG, HDL, FPG, HOMA-IR, steatosis, or fibrosis'. The positive results are OFF-OBJECT for a liver-FAT claim - AST k=9/n=549 SMD -0.40, GGT k=6 SMD -0.49, but ALT NULL k=10/n=574 SMD -0.22 P=0.15 - plus TC, LDL-C, hs-CRP, IL-6; HbA1c ROSE (k=3/n=141, SMD +0.40, P=0.02). Null on a directional claim = contradicts (CONVENTIONS 5). The prior extract's 'improved liver fat/aminotransferases (heterogeneous)' fails on all three counts: fat was null, ALT was null, and the deciding MRI-PDFF pool had I2=0%. Quality low: the paper reports 8/10 trials with no allocation-concealment detail and 'more than half' with bias concerns, pools nine different comparators (diet, statins, acarbose, polyene phosphatidylcholine), and applies Egger's at k=2-4 against its own stated >=10-study rule; its abstract omits every liver-fat null. INDEPENDENCE (flagged, not fixed): the MRI-PDFF pool IS ESSENTIAL (Cho 2022) + MOZART (Loomba 2015), both of which vote separately on this claim; names them correctly. |
| Loomba R, Sirlin CB, Ang B, et al. 2015 · Hepatology | RCT | contradicts | high | MOZART randomised placebo-controlled trial, liver fat by MRI-PDFF across nine colocalised segments plus MR elastography: 'Ezetimibe was NOT significantly better than placebo at reducing liver fat' (between-arm mean difference -1.3%, p=0.4). Within-arm fat fell in the ezetimibe group (15%->11.6%, p<0.016) but not placebo (18.5%->16.4%, p=0.15) - a within-arm change without a between-arm difference is not an effect. Well-powered imaging null on a directional claim -> contradicts per CONVENTIONS 5. |
| Xue F et al 2026 · study_type: RCT | RCT | contradicts | high | Phase 2a RCT, 210 Asian MASLD patients, 5 arms (HSK31679 3 doses, ezetimibe 10mg, placebo) for 12 weeks; primary endpoint relative change in MRI-PDFF liver fat content. Ezetimibe arm result not reported as significantly different from place |
| Xu Y et al 2026 · study_type: animal | animal | supports | moderate | Wild-type mice on NIAAA alcohol-feeding model +/- dietary cholesterol +/- ezetimibe (0.001% w/v); ezetimibe protected mice from cholesterol+alcohol-induced hepatic triglyceride accumulation and normalized liver cholesterol content, via enha |
| Masson 2025 · J Lipid Atheroscler | meta-analysis | mixed | moderate | [FT-verified] Masson2025 SR 18 studies/933: 5/8 ezetimibe RCTs no sig change; placebo-RCTs MOZART/LISTEN null; histo gains only non-RCT |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.